Medicare to boost payment for certain diagnostic imaging agents
Radiology Business
NOVEMBER 5, 2024
CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Radiology Business
NOVEMBER 5, 2024
CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.
AuntMinnie
MARCH 15, 2024
An emerging field of precision radiopharmaceuticals brings new optimism to this mission, revolutionizing cancer care. Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue. Precision radiopharmaceuticals represent a step toward better, longer lifespans for all.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
DECEMBER 6, 2023
and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today provided additional information regarding a March 2022 licensing and collaboration agreement between Philochem and Blue Earth Diagnostics.
Imaging Technology
APRIL 10, 2024
an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted therapeutic radiopharmaceutical, is the lead candidate in Blue Earth Therapeutics’ oncology development program of next generation therapeutic radiopharmaceuticals. 177Lu-rhPSMA-10.1,
Diagnostic Imaging
NOVEMBER 15, 2024
In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.
Imaging Technology
JULY 9, 2024
Campione also joins the Blue Earth Diagnostics Ltd. Board of Directors and will serve as Vice Chair of the Blue Earth Diagnostics Inc. “I Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., Bracco Imaging S.p.A., Bracco Imaging S.p.A.,
Diagnostic Imaging
JUNE 28, 2023
In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D.,
Open Medscience
AUGUST 8, 2019
Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. The post Radiometals for diagnostic imaging and theranostics appeared first on Open Medscience.
Diagnostic Imaging
JANUARY 24, 2025
In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Image courtesy of Washington University. "We Nuclear Regulatory Commission and is an integral part of a theranostics practice.
AuntMinnie
JUNE 3, 2024
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., Siegel told AuntMinnie.com. "My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
Imaging Technology
JUNE 10, 2024
The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto. More recently, she and her collaborators developed a PET imaging agent for vaso-occlusive crisis in sickle cell disease, recently approved for human studies by the FDA as an Investigational New Drug.
Imaging Technology
APRIL 3, 2023
produced, non-uranium based Mo-99 for use in diagnostic imaging. Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit.
Diagnostic Imaging
JANUARY 12, 2024
The FDA has accepted Lantheus' abbreviated new drug application for a generic Lutathera, just months after Novartis announced positive phase 3 data supporting a first-line indication for the radiopharmaceutical in neuroendocrine tumors.
Imaging Technology
MAY 30, 2023
milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Conventional imaging techniques such as CT and MRI are limited in the information they may provide.
AuntMinnie
OCTOBER 25, 2024
7-tesla MRI gets us closer in imaging to our pathology colleagues, and offers many new possibilities for better treatment," he said. Going forward, Middlebrooks plans to apply his skills to the further development of AI for image reconstruction. There's a huge role for AI in image acquisition," he said. Perry Pickhardt, MD.
Imaging Technology
MAY 2, 2023
milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 PET imaging currently under review by the U.S.
Imaging Technology
JUNE 29, 2023
milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 Blue Earth Diagnostics received U.S.
Open Medscience
JUNE 22, 2024
Radiotheranostics combines diagnostic imaging and targeted radiotherapy, using radiopharmaceuticals for personalised, precise cancer treatment and improved outcomes. The post What is Radiotheranostics? The Future of Personalised Cancer Diagnosis appeared first on Open MedScience.
TTG Imaging Solutions
FEBRUARY 17, 2022
Imaging Conference & Expo: February 20 – 22, 2022 TTG Imaging Solutions will be exhibiting at the Imaging Conference & Expo in Napa, CA. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook. Learn more about TTG in our video overview.
Open Medscience
SEPTEMBER 25, 2024
Radiotheranostic treatments combine diagnostic imaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness. The post Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications appeared first on Open MedScience.
Open Medscience
SEPTEMBER 14, 2024
Radiotheranostics offers a precise, personalised approach to cancer treatment by combining diagnostic imaging with targeted therapy The post The Future of Radiotheranostics: A New Frontier in Precision Medicine appeared first on Open MedScience.
Diagnostic Imaging
AUGUST 23, 2024
Currently in phase III trials, the 64Cu-SAR-bisPSMA PET agent reportedly offers a longer half-life and higher tumor uptake than other radiopharmaceuticals for prostate cancer imaging.
TTG Imaging Solutions
OCTOBER 20, 2021
The American Society for Radiation Oncology 2021 Annual Meeting: October 24 – 26 TTG Imaging Solutions is proud to be exhibiting at the American Society for Radiation Oncology Annual Meeting in Chicago, IL. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.
TTG Imaging Solutions
SEPTEMBER 28, 2021
The American Society of Nuclear Cardiology 2021 Virtual Annual Meeting: September 30 – October 2 TTG Imaging Solutions is proud to be a Bronze Sponsor at the American Society of Nuclear Cardiology Virtual Annual Meeting. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.
TTG Imaging Solutions
JANUARY 9, 2022
The American Society of Nuclear Cardiology Cardiac PET Intensive Virtual Workshop: Jan 14 – 16, 2022 TTG Imaging Solutions is proud to sponsor the American Society of Nuclear Cardiology Cardiac PET Intensive Virtual Workshop. For the latest updates on TTG Imaging Solutions, connect with us on LinkedIn , Twitter , and Facebook.
Diagnostic Imaging
JUNE 9, 2024
shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,
TTG Imaging Solutions
OCTOBER 27, 2021
The American Society of Nuclear Cardiology Cardiac PET Advanced Virtual Workshop – Oct 30 & 31, 2021 TTG Imaging Solutions is proud to be a Bronze Sponsor at the American Society of Nuclear Cardiology Cardiac PET Advanced Virtual Workshop. Request a meeting with one of our Regional Sales Managers at sales@ttgimagingsolutions.com.
Imaging Technology
JULY 28, 2023
It is the first and only FDA-approved, PSMA-targeted imaging agent developed with proprietary radiohybrid (rh) technology. POSLUMA is widely available through 36 radiopharmacies in the national network of Blue Earth Diagnostics’ commercial U.S. Chief Medical Officer of Blue Earth Diagnostics. POSLUMA was approved by the U.S.
TTG Imaging Solutions
MAY 5, 2023
Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA. Digirad Health, Inc.
TTG Imaging Solutions
NOVEMBER 1, 2021
PITTSBURGH, PA (November 1, 2021) – TTG Imaging Solutions, LLC (TTG) announced today executive leadership changes that will drive the company’s next phase of growth following its 9th acquisition in 2 years of Medical Imaging Technologies, an Akron, Ohio based nuclear medicine equipment and service organization.
Diagnostic Imaging
OCTOBER 4, 2024
The clearance may facilitate improved standardization and efficiency of dosimetry-guided, theranostic applications of radiopharmaceutical therapy.
Imaging Technology
JUNE 20, 2024
More than half of the world’s population is underserved and lacks access to essential health services, and two-thirds have no access to diagnostic imaging.
AuntMinnie
NOVEMBER 12, 2024
His lab team is currently focused on "implementing advanced techniques, such as parallel transmit, to achieve more consistent image quality and fully harness the power of 7T for every patient," Middlebrooks said. Avoiding certain sequences due to difficulties at 7T is not always practical.
Future Teleradiology
NOVEMBER 27, 2023
This blog post sheds light on recent breakthroughs in nuclear medicine, illuminating the innovative advancements that are shaping the future of medical imaging and treatment. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.
TRA Medical Imaging
JANUARY 17, 2025
Radiologists are medical doctors who specialize in interpreting imaging studies like X-rays, CT scans, MRIs, and ultrasounds to diagnose and guide treatment for various conditions. This rigorous training covers all imaging modalities, from X-rays to advanced techniques like MRI and PET/CT scans.
TTG Imaging Solutions
AUGUST 1, 2023
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.
TTG Imaging Solutions
AUGUST 1, 2023
Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.
Future Teleradiology
NOVEMBER 21, 2023
This blog explores the latest innovations in nuclear medicine, shedding light on cutting-edge technologies and breakthroughs that are reshaping the landscape of medical imaging and treatment. Highlight how this field merges principles of physics with medical applications for both diagnostic and therapeutic purposes.
Open Medscience
JUNE 22, 2024
Radiotheranostic Pairs combine diagnostic imaging with targeted radiotherapy, revolutionising personalised cancer treatment through enhanced precision and efficacy. The post Radiotheranostic Pairs: Bridging Diagnostics and Therapeutics in Cancer appeared first on Open MedScience.
Open Medscience
OCTOBER 19, 2024
Cancer radiotheranostics combines targeted radiotherapy and diagnostic imaging to provide personalised, precise, and effective cancer treatment. The post Cancer Radiotheranostics: The Future of Targeted Cancer Therapy appeared first on Open MedScience.
Imaging Technology
OCTOBER 5, 2023
Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Recently approved by the U.S. on behalf of Gary A.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content